Form 4/A for CRL Charles River Laboratories
Accepted 2024-03-25 00:00:00 ET · period of report 2024-01-29 · accession 0001127602-24-011098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-03-25 | 2024-01-29 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | F - Tax | $220.28 | -994 | 25.4K | -4% | -$219.0K |
| A | 2024-03-25 | 2024-01-29 | CRL | LaPlume Joseph W | EVP, Corp Strategy, Develop | A - Grant | $0.00 | +3,279 | 26.4K | +14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-29 | F | D | 994 | $220.28 | 25,418 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-29 | A | A | 3,279 | $0.00 | 26,412 | D | — | — | (F1) Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. |